| Mr Brooks Ross Greger Ii, CRNA | |
|
419 W 5th St, Odessa, TX 79761-5026 | |
| (432) 640-2401 | |
| Not Available |
| Full Name | Mr Brooks Ross Greger Ii |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 18 Years |
| Location | 419 W 5th St, Odessa, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073663688 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 688504 (Texas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| U S Anesthesia Partners Of Texas, Pa | 7315850351 | 2379 |
News Archive
Respira Therapeutics, a product development company focused on inhaled therapeutics to improve patients' lives, today announced the results of a clinical feasibility study of the Company's drug engine technology.
Mantle cell lymphoma is a very aggressive and difficult to treat cancer originated in blood cells and lymph nodes. To identify the molecular alterations responsible for this tumor, and facilitate the development of new treatments, a team of scientists led by Dr. Xose S. Puente and Dr. Carlos López-Otín, at University of Oviedo, and Dr. Sílvia Beà and Dr. Elias Campo, at IDIBAPS, Hospital Clínic, University of Barcelona, have sequenced the genomes of over 30 of lymphomas.
UT Southwestern Medical Center has been awarded more than $42 million to date for basic and patient-oriented research from the American Recovery and Reinvestment Act of 2009, the $787 billion stimulus package President Barack Obama signed into law in February.
Researchers from the Norwegian University of Science and Technology have had promising experimental results from using Botox as a weight loss tool in rats. The research group hopes to win approval for human testing in the near future.
Flowonix Medical, Inc., announced today that its newest product, the Patient Therapy Controller (PTC), has been approved for market release. The PTC interfaces with the company's Prometra platform of intrathecal infusion devices. A small, hand-held device with a touch-screen, the PTC allows the patient to initiate a bolus delivery of medication from the implanted pump.
› Verified 8 days ago
| Entity Name | U S Anesthesia Partners Of Texas, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548208564 PECOS PAC ID: 7315850351 Enrollment ID: O20031106000563 |
News Archive
Respira Therapeutics, a product development company focused on inhaled therapeutics to improve patients' lives, today announced the results of a clinical feasibility study of the Company's drug engine technology.
Mantle cell lymphoma is a very aggressive and difficult to treat cancer originated in blood cells and lymph nodes. To identify the molecular alterations responsible for this tumor, and facilitate the development of new treatments, a team of scientists led by Dr. Xose S. Puente and Dr. Carlos López-Otín, at University of Oviedo, and Dr. Sílvia Beà and Dr. Elias Campo, at IDIBAPS, Hospital Clínic, University of Barcelona, have sequenced the genomes of over 30 of lymphomas.
UT Southwestern Medical Center has been awarded more than $42 million to date for basic and patient-oriented research from the American Recovery and Reinvestment Act of 2009, the $787 billion stimulus package President Barack Obama signed into law in February.
Researchers from the Norwegian University of Science and Technology have had promising experimental results from using Botox as a weight loss tool in rats. The research group hopes to win approval for human testing in the near future.
Flowonix Medical, Inc., announced today that its newest product, the Patient Therapy Controller (PTC), has been approved for market release. The PTC interfaces with the company's Prometra platform of intrathecal infusion devices. A small, hand-held device with a touch-screen, the PTC allows the patient to initiate a bolus delivery of medication from the implanted pump.
› Verified 8 days ago
| Entity Name | Christus Trinity Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285684225 PECOS PAC ID: 3072426741 Enrollment ID: O20031204001091 |
News Archive
Respira Therapeutics, a product development company focused on inhaled therapeutics to improve patients' lives, today announced the results of a clinical feasibility study of the Company's drug engine technology.
Mantle cell lymphoma is a very aggressive and difficult to treat cancer originated in blood cells and lymph nodes. To identify the molecular alterations responsible for this tumor, and facilitate the development of new treatments, a team of scientists led by Dr. Xose S. Puente and Dr. Carlos López-Otín, at University of Oviedo, and Dr. Sílvia Beà and Dr. Elias Campo, at IDIBAPS, Hospital Clínic, University of Barcelona, have sequenced the genomes of over 30 of lymphomas.
UT Southwestern Medical Center has been awarded more than $42 million to date for basic and patient-oriented research from the American Recovery and Reinvestment Act of 2009, the $787 billion stimulus package President Barack Obama signed into law in February.
Researchers from the Norwegian University of Science and Technology have had promising experimental results from using Botox as a weight loss tool in rats. The research group hopes to win approval for human testing in the near future.
Flowonix Medical, Inc., announced today that its newest product, the Patient Therapy Controller (PTC), has been approved for market release. The PTC interfaces with the company's Prometra platform of intrathecal infusion devices. A small, hand-held device with a touch-screen, the PTC allows the patient to initiate a bolus delivery of medication from the implanted pump.
› Verified 8 days ago
| Entity Name | Mother Frances Hospital Regional Health Care Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679578439 PECOS PAC ID: 9234025636 Enrollment ID: O20040610001042 |
News Archive
Respira Therapeutics, a product development company focused on inhaled therapeutics to improve patients' lives, today announced the results of a clinical feasibility study of the Company's drug engine technology.
Mantle cell lymphoma is a very aggressive and difficult to treat cancer originated in blood cells and lymph nodes. To identify the molecular alterations responsible for this tumor, and facilitate the development of new treatments, a team of scientists led by Dr. Xose S. Puente and Dr. Carlos López-Otín, at University of Oviedo, and Dr. Sílvia Beà and Dr. Elias Campo, at IDIBAPS, Hospital Clínic, University of Barcelona, have sequenced the genomes of over 30 of lymphomas.
UT Southwestern Medical Center has been awarded more than $42 million to date for basic and patient-oriented research from the American Recovery and Reinvestment Act of 2009, the $787 billion stimulus package President Barack Obama signed into law in February.
Researchers from the Norwegian University of Science and Technology have had promising experimental results from using Botox as a weight loss tool in rats. The research group hopes to win approval for human testing in the near future.
Flowonix Medical, Inc., announced today that its newest product, the Patient Therapy Controller (PTC), has been approved for market release. The PTC interfaces with the company's Prometra platform of intrathecal infusion devices. A small, hand-held device with a touch-screen, the PTC allows the patient to initiate a bolus delivery of medication from the implanted pump.
› Verified 8 days ago
| Entity Name | Martin County Hospital District |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679560866 PECOS PAC ID: 8527958552 Enrollment ID: O20040805001106 |
News Archive
Respira Therapeutics, a product development company focused on inhaled therapeutics to improve patients' lives, today announced the results of a clinical feasibility study of the Company's drug engine technology.
Mantle cell lymphoma is a very aggressive and difficult to treat cancer originated in blood cells and lymph nodes. To identify the molecular alterations responsible for this tumor, and facilitate the development of new treatments, a team of scientists led by Dr. Xose S. Puente and Dr. Carlos López-Otín, at University of Oviedo, and Dr. Sílvia Beà and Dr. Elias Campo, at IDIBAPS, Hospital Clínic, University of Barcelona, have sequenced the genomes of over 30 of lymphomas.
UT Southwestern Medical Center has been awarded more than $42 million to date for basic and patient-oriented research from the American Recovery and Reinvestment Act of 2009, the $787 billion stimulus package President Barack Obama signed into law in February.
Researchers from the Norwegian University of Science and Technology have had promising experimental results from using Botox as a weight loss tool in rats. The research group hopes to win approval for human testing in the near future.
Flowonix Medical, Inc., announced today that its newest product, the Patient Therapy Controller (PTC), has been approved for market release. The PTC interfaces with the company's Prometra platform of intrathecal infusion devices. A small, hand-held device with a touch-screen, the PTC allows the patient to initiate a bolus delivery of medication from the implanted pump.
› Verified 8 days ago
| Entity Name | Northstar Anesthesia Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912978610 PECOS PAC ID: 7315907128 Enrollment ID: O20041015000685 |
News Archive
Respira Therapeutics, a product development company focused on inhaled therapeutics to improve patients' lives, today announced the results of a clinical feasibility study of the Company's drug engine technology.
Mantle cell lymphoma is a very aggressive and difficult to treat cancer originated in blood cells and lymph nodes. To identify the molecular alterations responsible for this tumor, and facilitate the development of new treatments, a team of scientists led by Dr. Xose S. Puente and Dr. Carlos López-Otín, at University of Oviedo, and Dr. Sílvia Beà and Dr. Elias Campo, at IDIBAPS, Hospital Clínic, University of Barcelona, have sequenced the genomes of over 30 of lymphomas.
UT Southwestern Medical Center has been awarded more than $42 million to date for basic and patient-oriented research from the American Recovery and Reinvestment Act of 2009, the $787 billion stimulus package President Barack Obama signed into law in February.
Researchers from the Norwegian University of Science and Technology have had promising experimental results from using Botox as a weight loss tool in rats. The research group hopes to win approval for human testing in the near future.
Flowonix Medical, Inc., announced today that its newest product, the Patient Therapy Controller (PTC), has been approved for market release. The PTC interfaces with the company's Prometra platform of intrathecal infusion devices. A small, hand-held device with a touch-screen, the PTC allows the patient to initiate a bolus delivery of medication from the implanted pump.
› Verified 8 days ago
| Entity Name | Christus Health Ark-la-tex |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184623266 PECOS PAC ID: 2264325588 Enrollment ID: O20050324001186 |
News Archive
Respira Therapeutics, a product development company focused on inhaled therapeutics to improve patients' lives, today announced the results of a clinical feasibility study of the Company's drug engine technology.
Mantle cell lymphoma is a very aggressive and difficult to treat cancer originated in blood cells and lymph nodes. To identify the molecular alterations responsible for this tumor, and facilitate the development of new treatments, a team of scientists led by Dr. Xose S. Puente and Dr. Carlos López-Otín, at University of Oviedo, and Dr. Sílvia Beà and Dr. Elias Campo, at IDIBAPS, Hospital Clínic, University of Barcelona, have sequenced the genomes of over 30 of lymphomas.
UT Southwestern Medical Center has been awarded more than $42 million to date for basic and patient-oriented research from the American Recovery and Reinvestment Act of 2009, the $787 billion stimulus package President Barack Obama signed into law in February.
Researchers from the Norwegian University of Science and Technology have had promising experimental results from using Botox as a weight loss tool in rats. The research group hopes to win approval for human testing in the near future.
Flowonix Medical, Inc., announced today that its newest product, the Patient Therapy Controller (PTC), has been approved for market release. The PTC interfaces with the company's Prometra platform of intrathecal infusion devices. A small, hand-held device with a touch-screen, the PTC allows the patient to initiate a bolus delivery of medication from the implanted pump.
› Verified 8 days ago
| Entity Name | Spine Team Texas Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629082995 PECOS PAC ID: 6507888757 Enrollment ID: O20051230000616 |
News Archive
Respira Therapeutics, a product development company focused on inhaled therapeutics to improve patients' lives, today announced the results of a clinical feasibility study of the Company's drug engine technology.
Mantle cell lymphoma is a very aggressive and difficult to treat cancer originated in blood cells and lymph nodes. To identify the molecular alterations responsible for this tumor, and facilitate the development of new treatments, a team of scientists led by Dr. Xose S. Puente and Dr. Carlos López-Otín, at University of Oviedo, and Dr. Sílvia Beà and Dr. Elias Campo, at IDIBAPS, Hospital Clínic, University of Barcelona, have sequenced the genomes of over 30 of lymphomas.
UT Southwestern Medical Center has been awarded more than $42 million to date for basic and patient-oriented research from the American Recovery and Reinvestment Act of 2009, the $787 billion stimulus package President Barack Obama signed into law in February.
Researchers from the Norwegian University of Science and Technology have had promising experimental results from using Botox as a weight loss tool in rats. The research group hopes to win approval for human testing in the near future.
Flowonix Medical, Inc., announced today that its newest product, the Patient Therapy Controller (PTC), has been approved for market release. The PTC interfaces with the company's Prometra platform of intrathecal infusion devices. A small, hand-held device with a touch-screen, the PTC allows the patient to initiate a bolus delivery of medication from the implanted pump.
› Verified 8 days ago
| Entity Name | Northstar Anesthesia Ii Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477066405 PECOS PAC ID: 2365701737 Enrollment ID: O20180110000102 |
News Archive
Respira Therapeutics, a product development company focused on inhaled therapeutics to improve patients' lives, today announced the results of a clinical feasibility study of the Company's drug engine technology.
Mantle cell lymphoma is a very aggressive and difficult to treat cancer originated in blood cells and lymph nodes. To identify the molecular alterations responsible for this tumor, and facilitate the development of new treatments, a team of scientists led by Dr. Xose S. Puente and Dr. Carlos López-Otín, at University of Oviedo, and Dr. Sílvia Beà and Dr. Elias Campo, at IDIBAPS, Hospital Clínic, University of Barcelona, have sequenced the genomes of over 30 of lymphomas.
UT Southwestern Medical Center has been awarded more than $42 million to date for basic and patient-oriented research from the American Recovery and Reinvestment Act of 2009, the $787 billion stimulus package President Barack Obama signed into law in February.
Researchers from the Norwegian University of Science and Technology have had promising experimental results from using Botox as a weight loss tool in rats. The research group hopes to win approval for human testing in the near future.
Flowonix Medical, Inc., announced today that its newest product, the Patient Therapy Controller (PTC), has been approved for market release. The PTC interfaces with the company's Prometra platform of intrathecal infusion devices. A small, hand-held device with a touch-screen, the PTC allows the patient to initiate a bolus delivery of medication from the implanted pump.
› Verified 8 days ago
| Entity Name | Trinity Medical Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932611654 PECOS PAC ID: 4587926357 Enrollment ID: O20180315001642 |
News Archive
Respira Therapeutics, a product development company focused on inhaled therapeutics to improve patients' lives, today announced the results of a clinical feasibility study of the Company's drug engine technology.
Mantle cell lymphoma is a very aggressive and difficult to treat cancer originated in blood cells and lymph nodes. To identify the molecular alterations responsible for this tumor, and facilitate the development of new treatments, a team of scientists led by Dr. Xose S. Puente and Dr. Carlos López-Otín, at University of Oviedo, and Dr. Sílvia Beà and Dr. Elias Campo, at IDIBAPS, Hospital Clínic, University of Barcelona, have sequenced the genomes of over 30 of lymphomas.
UT Southwestern Medical Center has been awarded more than $42 million to date for basic and patient-oriented research from the American Recovery and Reinvestment Act of 2009, the $787 billion stimulus package President Barack Obama signed into law in February.
Researchers from the Norwegian University of Science and Technology have had promising experimental results from using Botox as a weight loss tool in rats. The research group hopes to win approval for human testing in the near future.
Flowonix Medical, Inc., announced today that its newest product, the Patient Therapy Controller (PTC), has been approved for market release. The PTC interfaces with the company's Prometra platform of intrathecal infusion devices. A small, hand-held device with a touch-screen, the PTC allows the patient to initiate a bolus delivery of medication from the implanted pump.
› Verified 8 days ago
| Entity Name | Northstar Anesthesia Iii Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356968952 PECOS PAC ID: 0042630501 Enrollment ID: O20201022000080 |
News Archive
Respira Therapeutics, a product development company focused on inhaled therapeutics to improve patients' lives, today announced the results of a clinical feasibility study of the Company's drug engine technology.
Mantle cell lymphoma is a very aggressive and difficult to treat cancer originated in blood cells and lymph nodes. To identify the molecular alterations responsible for this tumor, and facilitate the development of new treatments, a team of scientists led by Dr. Xose S. Puente and Dr. Carlos López-Otín, at University of Oviedo, and Dr. Sílvia Beà and Dr. Elias Campo, at IDIBAPS, Hospital Clínic, University of Barcelona, have sequenced the genomes of over 30 of lymphomas.
UT Southwestern Medical Center has been awarded more than $42 million to date for basic and patient-oriented research from the American Recovery and Reinvestment Act of 2009, the $787 billion stimulus package President Barack Obama signed into law in February.
Researchers from the Norwegian University of Science and Technology have had promising experimental results from using Botox as a weight loss tool in rats. The research group hopes to win approval for human testing in the near future.
Flowonix Medical, Inc., announced today that its newest product, the Patient Therapy Controller (PTC), has been approved for market release. The PTC interfaces with the company's Prometra platform of intrathecal infusion devices. A small, hand-held device with a touch-screen, the PTC allows the patient to initiate a bolus delivery of medication from the implanted pump.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Brooks Ross Greger Ii, CRNA 6313 Prairie Ridge Dr, Midland, TX 79707-5067 Ph: (469) 383-9991 | Mr Brooks Ross Greger Ii, CRNA 419 W 5th St, Odessa, TX 79761-5026 Ph: (432) 640-2401 |
News Archive
Respira Therapeutics, a product development company focused on inhaled therapeutics to improve patients' lives, today announced the results of a clinical feasibility study of the Company's drug engine technology.
Mantle cell lymphoma is a very aggressive and difficult to treat cancer originated in blood cells and lymph nodes. To identify the molecular alterations responsible for this tumor, and facilitate the development of new treatments, a team of scientists led by Dr. Xose S. Puente and Dr. Carlos López-Otín, at University of Oviedo, and Dr. Sílvia Beà and Dr. Elias Campo, at IDIBAPS, Hospital Clínic, University of Barcelona, have sequenced the genomes of over 30 of lymphomas.
UT Southwestern Medical Center has been awarded more than $42 million to date for basic and patient-oriented research from the American Recovery and Reinvestment Act of 2009, the $787 billion stimulus package President Barack Obama signed into law in February.
Researchers from the Norwegian University of Science and Technology have had promising experimental results from using Botox as a weight loss tool in rats. The research group hopes to win approval for human testing in the near future.
Flowonix Medical, Inc., announced today that its newest product, the Patient Therapy Controller (PTC), has been approved for market release. The PTC interfaces with the company's Prometra platform of intrathecal infusion devices. A small, hand-held device with a touch-screen, the PTC allows the patient to initiate a bolus delivery of medication from the implanted pump.
› Verified 8 days ago
Benedict Castanares Novicio, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 500 W 4th St, Odessa, TX 79761 Phone: 432-640-2408 Fax: 432-640-2190 | |
Bonnie Longnecker, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 520 E 6th St, Odessa, TX 79761 Phone: 432-332-0929 | |
Scott Madewell, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 520 E 6th St, Odessa, TX 79761 Phone: 432-334-8088 Fax: 432-580-7202 | |
Charles Richard Fox, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 520 E 6th St, Odessa, TX 79761 Phone: 432-334-8088 Fax: 432-580-7202 | |
Jordan Crumrine, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 520 E 6th St, Odessa, TX 79761 Phone: 432-332-0929 Fax: 888-575-9993 | |
John W Presley, CRNA Nurse Anesthetist - CR Medicare: May Accept Medicare Assignments Practice Location: 500 W 4th St, Odessa, TX 79761 Phone: 432-640-4000 Fax: 432-640-4606 |